Learn what zavegepant is, how this next-generation CGRP receptor antagonist works, and why its fast-acting nasal spray formulation is a game-changer for acute migraine treatment, especially for patients with nausea or vomiting.
Learn what zavegepant is, how this intranasal CGRP receptor antagonist works for acute migraine treatment, and why its non‑vasoconstrictive, needle‑free nasal spray delivery may benefit patients with nausea or cardiovascular risk factors.
Learn what atogepant is, how this oral CGRP receptor antagonist works, and why migraine specialists are excited about its once‑daily dosing and clinical trial results for episodic and chronic migraine prevention.
Learn how erenumab (Aimovig), a CGRP receptor‑blocking monoclonal antibody, differs from traditional migraine drugs like beta‑blockers and antidepressants. Explore its targeted mechanism, once‑monthly dosing, and clinical trial results for episodic and chronic migraine prevention.
Learn what zavegepant is, how this intranasal CGRP receptor antagonist differs from traditional triptans, and review key clinical trial evidence on its speed, effectiveness, and safety for acute migraine treatment.
Learn how erenumab, a CGRP receptor–blocking monoclonal antibody, is transforming migraine prevention. Discover its mechanism, benefits for episodic and chronic migraine, and why it outperforms many traditional oral preventives.
Learn what zavegepant is, how its intranasal CGRP receptor blockade works, and why it’s emerging as a fast, needle‑free option for acute migraine relief and prevention.
Learn how zavegepant, the first intranasal CGRP receptor antagonist, offers fast-acting, targeted relief for acute migraine—especially for patients who can’t tolerate oral medications or need rapid onset of action.